To investigate the role of forkhead box protein M1 (FOXM1) mRNA expression and its prognostic value in stage pT1 nonmuscle-invasive bladder cancer (NMIBC).
Patients and Methods
Clinical data and formalin-fixed paraffin-embedded tissues from transurethral resection of the bladder from patients with stage pT1 NMIBC, treated with an organ-preserving approach, were analysed retrospectively. Total RNA was isolated using commercial RNA extraction kits, and mRNA expression of FOXM1, MKI67, KRT20 and KRT5 was measured by singlestep quantitative RT-PCR using RNA-specific TaqMan Assays. Statistical analysis was performed using Spearman's Rho, Wilcoxon or Kruskal-Wallis tests, Kaplan-Meier estimates of recurrence-free (RFS), progression-free (PFS) and cancerspecific survival (CSS) and Cox regression analysis.
Results
Data from 296 patients (79.4% men, median age 72 years) were available for the final evaluation. Spearman correlation analysis showed that mRNA expression of FOXM1 was significantly correlated with MKI67 (q: 0.6530, P < 0.001) and with the luminal subtype, reflected by the positive correlation with KRT20 (q: 0.2113, P < 0.001). Furthermore, there was also a strong correlation of FOXM1 expression with adverse clinical and pathological variables, such as concomitant carcinoma in situ (P = 0.05), multifocal tumours (P = 0.005) and World Health Organization 1973 grade 3 disease (P < 0.001). Kaplan-Meier analysis showed overexpression of FOMX1 to be associated with worse PFS (P = 0.028) and worse CSS (P = 0.015). FOXM1 overexpression was also shown to be a predictive risk factor for CSS (hazard ratio 1.61 [1.13-2.34], L-R chi-squared: 7.19, P = 0.007). FOXM1 overexpression identified a subgroup of patients within the luminal subtype with worse RFS (P = 0.017), PFS (P < 0.001) and CSS (P = 0.015). Patients with low FOXM1 expression had better outcomes, irrespective of instillation therapy, whereas patients with high FOXM1 expression benefitted from intravesical chemotherapy with mitomycin C.
Introduction
Urothelial carcinoma of the bladder represents the ninth most common malignancy worldwide [1] . Approximately 75% of the patients are initially diagnosed with non-muscle-invasive bladder cancer (NMIBC), and 25% are initially diagnosed with muscle-invasive bladder cancer (MIBC) [2] . Patients with NMIBC are treated with transurethral resection of the bladder (TURB), followed by intravesical instillation therapy with BCG or mitomycin C (MMC), depending on pathological and clinical prognostic characteristics [2, 3] . Recurrence of NMIBC occurs in 50-70% of patients and, in up to 20% of patients, the tumour will progress to a more invasive stage, depending on stage and grade after TURB [2, 4] .
At stage pT1, NMIBC remains the most challenging entity, with an estimated 30% of the patients with T1G3 tumours experiencing progression and another 30% dying from the disease [5] . Besides cystoscopic monitoring, patients with pT1 NMIBC are treated with maintenance therapy with BCG or early cystectomy [2] . It has been shown that patients with stage pT1G3 tumours benefit from early cystectomy, which provides the best oncological safety [6] ; however, many patients will be overtreated by cystectomy, which has a perioperative 90-day mortality rate of up to 9% and is associated with side effects such as incontinence and sexual dysfunction [7] . The lack of strong indicators for immediate or early cystectomy, combined with the side effects, leads to individualized treatment decisions in patients with high-risk or highest risk T1 bladder cancer.
The forkhead box (FOX) family belongs to a large family of transcription factors evolutionarily conserved in the winged helix/forkhead DNA binding domain [8] . FOX protein M1 (FOXM1) expression is induced in embryogenesis, in tissue repair in organ injury and in carcinogenesis [8] . It is ubiquitously expressed in proliferating cells, promoting proliferation [9] . Overexpression of FOXM1, therefore, plays an important role in carcinogenesis via induction of proliferation, inhibition of cell aging and apoptosis via suppression of p53 [10, 11] . Furthermore, tumour invasion and metastasis are induced by FOXM1 via epithelial-mesenchymal transition, the expression of matrix-metalloproteinases and angiogenesis via upregulation of vascular endothelial growth factor [12] [13] [14] .
For diverse solid tumours, including breast cancer, gastric cancer, hepatocellular carcinoma, pancreatic duct carcinoma, non-small-cell lung cancer and ovarian cancer, a correlation between overexpression of FOXM1 and worse outcome has been demonstrated [10] .
More recently, it has been shown that FOXM1 expression increases with stage and grade of bladder cancer and overexpression of FOXM1 has been linked to more aggressive bladder cancer subtypes [15] [16] [17] . Rinaldetti et al. [16] showed that overexpression of FOXM1 results in worse overall survival (OS) and cancer-specific survival (CSS) in MIBC. Hedegaard et al. [17] proposed three subtypes of NMIBC, of which class 2 is associated with the worst progression-free survival (PFS). Class 2 tumours presented an overexpression of FOXM1 as well as of other proteins [17] .
Stage pT1 is the sub-entity of bladder cancer associated with the most momentous treatment decision (bladder-sparing vs early cystectomy), as described above. The aim of the present study, therefore, was to investigate the prognostic role of FOXM1 mRNA expression in a large cohort of solely pT1 tumours and to link the FOXM1 expression with a previously described subtype classification in pT1 NMIBC and with response to instillation therapy [18] .
Patients and Methods

Study Population
The study cohort consisted of 334 patients with stage pT1 NMIBC at initial diagnosis who underwent TURB at a single centre between 1989 and 2012. Patients with previously diagnosed bladder cancer of any stage were excluded. All patients included in the study underwent re-resection 6 weeks after initial resection and were initially treated according to an organ-preserving approach. Histopathological variables of all cases, including grading according to WHO 1973 and WHO 2016 classification were reassessed by a pathologist specializing in uropathology (A.H.). Follow-up was recorded retrospectively after approval from the local ethics committee (08/108).
Isolation of Tumour RNA
For RNA extraction from formalin-fixed paraffin-embedded tissue, a single 10-lm curl was processed according to a commercially available bead-based extraction method (XTRACT kit; STRATIFYER Molecular Pathology GmbH, Cologne, Germany). RNA was eluted with 100 lL elution buffer, and RNA eluates were then stored at À80°C until use.
Gene Expression by Quantitative RT-PCR
The mRNA expression levels of FOXM1, KRT5, KRT20 and MKI67, as well as one reference gene, namely, calmodulin (CALM2), were determined by quantitative RT-PCR, which involves reverse transcription of RNA and subsequent amplification of cDNA executed successively as a one-step reaction using Taqman Primer/Probes. The robustness and usefulness of CALM2 as a housekeeping gene for diverse candidate genes has been demonstrated in multiple publications by our group [18, 19] and resulted its introduction as a housekeeping gene in communaut e europ eenne-certified in vitro diagnostics products such as Endopredict [20] .
Each patient or control sample was analysed with each assay mix in triplicate. The experiments were run on a Versant kPCR system (Siemens, Erlangen, Germany) according to the following protocol: 5 min at 50°C, 20 s at 95°C followed by 40 cycles of 15 s at 95°C and 60 s at 60°C.
Forty amplification cycles were applied, and the cycle threshold (ct) values of three markers and one reference gene for each sample were estimated as the median of the triplicate measurements. The final values were generated by using Dct from the total number of cycles to ensure that the normalized gene expression obtained by the test was proportional to the corresponding mRNA expression levels.
Statistical Methods
The Spearman product-moment correlation coefficient r was used as a measure of the strength and direction of the linear relationship between variables. The Wilcoxon/Kruskal-Wallis test was performed to correlate mRNA expression with clinical and pathological variables. Statistical analysis, including Kaplan-Meier survival analysis, multivariate Cox regression and partitioning testing were performed with SPSS version 23 (IBM Germany, Ehningen, Germany), JMP SAS (SAS Institute, Cary, NC, USA) and Graph Pad PRISM software (version 5.04; Graph Pad Software Inc., La Jolla, CA, USA).
Results
Patient Population
A total of 334 cases were found to be stage pT1 in initial histopathological assessment and confirmed in a histopathological reassessment in 2015/2016. After exclusion of 38 samples because of low RNA yields, data from 296 patients (79.4% men, median age 72 years) were used for the final evaluation. Of these, 32% were graded as G2 and 68% were graded as G3 according to the 1973 WHO grading system ( Table 1 ). The median follow-up time was 42 months. Median mRNA expression and quartiles for FOXM1 mRNA expression were determined based on normalized FOXM1 RNA expression data. The exact cut-off values are depicted in the data distribution chart shown in Fig. S1 , with a FOXM1 mRNA expression value below 40-Dct of 33.055 being quartile 1, ≥33.055 and <33.965 being quartile 2, ≥33.965 and <34.61 being quartile 3 and ≥34.61 being quartile 4 ( Fig. S1 ). Median mRNA expression was measured as follows: FOXM1: 33.97; KRT20: 40.53; KRT5: 36.44; and MKI67: 36.39 (Fig. S1 ).
FOXM1 mRNA Expression Correlates with the Luminal Subtype, Proliferation and Adverse Clinicopathological Characteristics
Non-parametric Spearman rank correlation indicated a positive, statistically significant association between mRNA expression, measured by quantitative RT-PCR, and both FOXM1 and MKI67, representing proliferative activity (q: 0.6530, P < 0.001). Furthermore, a positive correlation with KRT20 mRNA expression (q: 0.2113, P < 0.001) and a negative correlation with KRT5 mRNA expression (q: À0.2076, P < 0.001), reflecting the luminal subtype as described earlier [18] , could be observed (Fig. S2 ).
To correlate FOXM1 mRNA expression with clinical and pathological characteristics, the non-parametric Wilcoxon/ Kruskal-Wallis test was performed. A significant association between high FOXM1 mRNA expression and adverse clinical and pathological characteristics, such as concomitant carcinoma in situ (CIS; P = 0.05), multifocal tumours (P = 0.005) and WHO 1973 grade 3 (P < 0.001) was observed ( Table 2) .
High FOXM1 mRNA Expression Predicts Poor Survival
Stratified by quartile of FOMX1 mRNA expression, KaplanMeier analysis showed a significant association between high FOXM1 mRNA expression in the highest quartile (quartile 4, ≥34.61) with worse PFS (P = 0.028) and worse CSS (P = 0.015; Fig. 1 ). No statistically significant association with recurrence-free survival (RFS) was observed (Fig. 1 Table 3 ).
When FOXM1 expression was included in the multivariate analysis as a continuous variable and not categorized based on quartile of mRNA expression it remained significant for CSS (P = 0.003), together with tumour size (P = 0.002), while gender, concomitant CIS, WHO 1973 grade and focality were not significant (Fig. S3 ). FOXM1 as a continuous variable was not significant for RFS (P = 0.103) or PFS (P = 0.666; Fig. S3 ).
High FOXM1 mRNA Expression Identifies a Subgroup of Patients within the Luminal Subtype with Worse Outcome
As Spearman correlation analysis showed a large statistically significant association between FOXM1 and KRT20 mRNA expression reflecting the luminal subtype, we investigated the prognostic role of FOXM1 expression in this subtype. High FOXM1 mRNA expression in the upper quartile (≥34.61) identified a subgroup of patients with the luminal subtype, reflected by high KRT20 expression (>40.26), with worse RFS (P = 0.017), PFS (P < 0.001) and CSS rates (P = 0.015; Fig. 2 ).
FOXM1 Overexpression Predicts Response to Instillation Therapy
Because approximately half of the patients received instillation therapy, the cohort was stratified into two groups: those with and those without instillation therapy (either BCG or MMC). Patients with no instillation therapy and high FOXM1 mRNA expression (above the median, ≥33.965) had the worst RFS (P = 0.059), PFS (P = 0.033) and CSS rates (P < 0.001; Fig. 3) . Interestingly, patients with high FOXM1 expression who received instillation therapy had almost identical RFS, PFS and CSS rates to patients with low FOXM1 expression without instillation therapy (Fig. 3 ).
Looking at high expressing tumours alone, patients who received instillation therapy with chemotherapy (MMC) had better RFS (P = 0.035), PFS (P = 0.01) and CSS rates (P < 0.001) than those who did not receive instillation therapy. Interestingly, patients who received instillation immunotherapy (BCG) had worse RFS, PFS and CSS rates than those who received intravesical chemotherapy (Fig. 4) .
Discussion
FOXM1 is expressed during embryogenesis, tissue repair and carcinogenesis [8] . It plays a role in different hallmarks of tumorigenesis and metastasis. Overexpression of FOXM1 has been shown to be associated with proliferation, and inhibits cell aging and apoptosis [10] . Furthermore, it promotes metastasis by regulating epithelial-mesenchymal transition [12] , expression of matrix-metalloproteinases [13] and angiogenesis via upregulation of vascular endothelial growth factor [14] . Because p53 inactivation leads to upregulation of FOXM1 and induction of p53 leads to downregulation of FOXM1, it has been proposed as a surrogate marker of inactivation of the tumour supressor p53 [16, 21] . In addition to these mechanistic and functional roles, overexpression of FOXM1 has been shown to be associated with worse outcome in various solid tumour entities, such as breast cancer and gastric cancer [10] .
In the present study, we investigated the role of FOXM1 in a retrospective cohort of patients solely with pT1 NMIBC. This is the only and largest cohort of such patients in which this role has been examined. We were able to show a strong correlation between high FOXM1 and MKI67 mRNA expression, indicating that high FOXM1 expression is associated with higher proliferative activity in those tumours. This is consistent with observations in several other studies. It has been shown that FOXM1 is ubiquitously expressed in proliferating cells, and FOXM1 promotes proliferation [9] . Likewise, a downregulation of FOXM1 leads to an inhibition of proliferation [22] .
In addition to this association with proliferative activity, we showed that FOXM1 expression was associated with adverse clinical and pathological tumour features such as concomitant CIS, multifocal tumours and WHO 1973 G3 tumours. These are well-known and established prognostic markers for NMIBC and have been implemented in the European Organization for Research and Treatment of Cancer (EORTC) score to predict recurrence and progression of NMIBC [23] . This is the first time that a correlation between higher FOXM1 expression and concomitant CIS and multifocality has been shown. With regard to tumour grade, for bladder cancer as well as for other tumour entities, such as breast cancer, an association between high grade tumours and high FOXM1 expression has been shown [22, 24, 25] . These findings indicate that higher expression of FOXM1 is a feature of more aggressive NMIBC at stage pT1.
Regarding the prognostic impact of high FOXM1 mRNA expression, we identified expression within the upper quartile as being associated with the worst PFS and CSS rates. Hedegaard et al. [17] investigated a large cohort of patients with NMIBC (mixed pTa and pT1) and identified that the subgroup of class 2 tumours with overexpression of FOXM1 were also associated with the worst outcomes. For MIBC, Rinaldetti et al. [16] showed that overexpression of FOXM1 was associated with worse CSS and OS, and was the best predictive factor in multivariable analysis. For other tumour entities, such as breast cancer [25] , gastric cancer, hepatocellular carcinoma [26] , pancreatic duct carcinoma, non-small-cell lung cancer and ovarian cancer [10] , the negative prognostic impact of high FOXM1 expression has been shown. Previously, we showed that the luminal subtype, indicated by high KRT20 and low KRT5 expression, was associated with worse outcomes in patients with pT1 NMIBC [18] . This was also observed in an independent NMIBC cohort of mixed pTa and pT1 tumours by Hedegaard et al. [17] , in which the tumours defined in the present study as class 2 were characterized by high KRT20 and low KRT5 expression as well as by other proteins. These class 2 tumours had the worst outcomes and were furthermore characterized by overexpression of FOXM1 [17] . We therefore investigated a possible correlation of FOXM1 with this luminal/class 2 subtype of NMIBC in our cohort of patients with pT1 tumours. As expected, a high positive significant correlation between FOXM1 and KRT20 and a high negative significant correlation between FOXM1 and KRT5 mRNA expression was observed; thus, we demonstrated an association of FOXM1 with the more aggressive subtype in pT1 NMIBC. Furthermore, we showed that, within this more aggressive subtype, reflected by high KRT20 mRNA expression, high FOXM1 expression identified a subgroup with even worse outcome and thus might be more suited to identify patients at high risk of progression and death from bladder cancer, who might benefit from early cystectomy. Stage pT1 earlyinvasive bladder cancer always represents a high-risk, or even highest-risk, situation, where early cystectomy should be considered as an alternative to the bladder-sparing approach by instillation therapy; however, it is still not possible to identify those who will experience tumour progression and those who will benefit from early radical cystectomy clearly, and treatment is an individualized decision to be made with the patient. Radical cystectomy is associated with high morbidity and 90-day mortality rates of up to 8% [2] ; however, early cystectomy is associated with improved longterm CSS in the subgroup of high-risk T1G3 tumours [6] . We previously showed that KRT20 expression was able to identify a subgroup of patients at highest risk from among those patients with pT1G3 tumours [18] ; thus, adding FOXM1 expression would further support a decision for early radical cystectomy.
To date, there has been no consistent nomenclature for molecular subgroups in NMIBC. Eriksson et al. [15] showed that FOXM1 is overexpressed in genitourinary-like and squamous cell carcinoma (SCC)-like subtypes of bladder cancer, which are also characterized by a high proliferative potential. Patschan et al. [27] observed that those genitourinary-like and SCC-like tumours have a worse PFS than urobasal tumours in a T1 NMIBC cohort. As described by Sj€ odahl et al. [28] , the genitourinary-like subtype is characterized by high KRT20 and low KRT5 expression with an intermediate outcome over all stages and grades of bladder cancer, whereas the SCC-like subtype shows low KRT20 and high KRT5 expression and has the worst outcome over all stages and grades. There might be differences regarding the prognostic potential of KRT expression in NMIBC and MIBC, but the common feature of these aggressive tumours is the high FOXM1 expression, which was also observed in the present study, consisting solely of T1 NMIBC.
Correlating FOXM1 mRNA expression with outcomes according to whether or not the patient received instillation therapy, we found that patients with low FOXM1 expression without instillation therapy had similar RFS, PFS and CSS rates to patients who received instillation therapy, irrespective of FOXM1 expression. This is consistent with the results discussed above, indicating that low FOXM1-expressing tumours are less aggressive. These patients might be suited to just undergoing follow-up without any instillation therapy; however, this needs to be validated in a prospective setting. The more aggressive tumours with high FOXM1 expression do respond to instillation therapy, especially to intravesical chemotherapy with MMC. The retrospective nature of the present study means that its data on instillation therapy represent a 'real-life' setting, in which not every patient receives the required instillation therapy with BCG. Recently, it has been shown that adherence to guidelines for administering BCG therapy for high-risk NMIBC is 65% in Europe and 29% in North America [29] . More recently, Ieda et al. [30] showed that only 38% of 1497 patients with NMIBC received instillation therapy. The present cohort would therefore seem to be representative. The finding that tumours with high FOXM1 mRNA expression showed better response to MMC than to BCG should also be further investigated, ideally in a prospective cohort. For other entities, such as breast cancer or gastric cancer, FOXM1 expression has been correlated with resistance to chemotherapy [31] [32] [33] . To date, this is the first investigation of the influence of FOXM1 expression on the response to instillation therapy in stage pT1 NMIBC. The results need to be validated, however, in a prospective setting, as discussed above.
In conclusion, in a large cohort of patients with solely pT1 NMIBC, we showed that high FOXM1 expression was associated with adverse clinical and pathological tumour features and adverse outcomes. Furthermore, we found that patients with low FOXM1 expression without instillation therapy had similar RFS, PFS and CSS rates to patients who received instillation therapy. High-expressing tumours showed a better response to MMC than to BCG. These findings need to be confirmed in a multicentre, prospective setting.
FOXM1 could be a potential future prognostic marker to identify patients who are at risk of progression and cancer-specific mortality in this challenging sub-entity of NMIBC and might help to select patients for individualized therapy. Fig. S1 . Data distribution of FoxM1, MKI67, KRT5 and KRT20 mRNA levels in T1 cohort. Fig. S2 . Correlation of FoxM1, MKI67, KRT5 and KRT20, mRNA mRNA levels. 
